Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells

Posted By Marcus Curl on 6/27/19 8:29 PM

rhLIF App Note #1 Download CTA ButtonWorkflow Summary:

Applying neural stem cells (NSC) as a cell therapy has created new hope for the treatment of various neural degenerative diseases as well as the reversal of neural damage once thought to be irreparable. Currently, clinical trials are being performed to evaluate NSC for the treatment of stroke, Parkinson’s disease, spinal cord injuries, and many other indications [1]. As new potential applications emerge and new clinical trials begin, the need for scalable and safe sources of the foundational cell culture materials becomes essential to the future of this technology. The ability to quickly and reliably expand neural NSCs in culture has therefore been essential to the exploration of these novel, cell-based therapeutic approaches. The goal of this application note is to provide step-by-step instructions for using InVitria’s recombinant hLIF in the efficient, safe, and scalable expansion of NSC in culture.

Read More

Reconstitution of Cellastim S for Cell-Culture Applications

Posted By Marcus Curl on 6/18/19 8:53 AM

Workflow Summary:Cellastim S Reconstitution Application Note #2 Download CTA Button

Human serum albumin (HSA) has been identified as a powerful tool for the expansion of many cell types in vitro [1]. HSA is a multifaceted protein capable of binding many different types of molecules [2]. HSA therefore plays diverse roles in cell biology, acting as an antioxidant to improve health of cells by binding to reactive oxygen species, as an energy-delivery system by chaperoning fatty acids in the bloodstream, and as a mediator for solubilization and stabilization of metal ions required for cellular processes [2,3]. These functions make HSA supplementation of cell culture media an integral step in facilitating cell growth and expansion in vitro, especially when removing serum or blood-derived proteins for use in clinical manufacturing. Using Cellastim S as a recombinant and scalable source of albumin in cell culture is an enabling tool for large-scale manufacture of cell-based and gene therapies. It is the goal of this app note to provide a step-by-step overview for preparing Cellastim S for use as a stock liquid solution for in vitro cell culture applications.

Read More

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Posted By Scott Deeter on 6/10/19 2:12 PM

Last week was the annual Biotechnology Industry Organization (BIO) annual convention in Philadelphia where medical innovations were abundant and showed remarkable promise. More than 17,000 delegates representing government, academia, and non-profit research institutes joined more than 4,000 companies in the City of Brotherly Love. The delegates share a common commitment to improve the quality and longevity of life through development of innovative new technologies, many of which are being commercialized at a pace not seen before. From vaccines to cell therapies and gene therapies, new products are promising substantial improvements to human health.

Read More

Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells

Posted By Marcus Curl on 5/29/19 1:00 PM

InVitira Optiferrin App Note 1 Download CTAIntroduction:

A growing number of clinical cases have provided strong proof of concept that hematopoietic stem-cell (HSC) therapies are potential treatments of blood cancers and many other debilitating diseases that were once thought to be incurable [1]. A critical tool to enable development of these therapies is expansion of HSCs in vitro [2]. However, supplementation of HSC growth media with serum-derived media supplements such as those included in xeno-free media and other animal-derived components can introduce adventitious pathogenic agents, create variability when cell expansion processes are scaled up for manufacturing, and can also present the risk of a supply chain interruption for clinical product manufacturing.

Read More

T Regulatory Cells, The Next T Cell Frontier?

Posted By Randy Alfano Ph.D. on 5/28/19 8:09 AM

Recently I had the opportunity to attend the Treg Summit in Boston to listen to the ground-breaking clinical and preclinical research in re-balancing the immune system in the context of autoimmunity and organ transplant via the use of polyclonal or antigen-induced T regulatory cells. Overall, this cell therapy holds immense promise as evidenced by both preclinical models and early clinical evaluations.

Read More